Literature DB >> 25209890

The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation.

Neslihan Kurtulmus1, Meral Mert, Refik Tanakol, Sema Yarman.   

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease in which the most common endocrine manifestation is diabetes insipidus (DI). Data on anterior pituitary function in patients with LCH are limited. Thus, the present study investigated anterior pituitary function in LCH patients with DI via the evaluation of clinical and radiological findings at disease onset and during follow-up. The present study retrospectively evaluated nine patients with LCH (five males and four females). All diagnoses of LCH were made following histological and/or immunophenotypic analyses of tissue biopsies, bronchoalveolar lavage, or cerebrospinal fluid (CSF). Basal and, if necessary, dynamic pituitary function tests were used to assess anterior pituitary function, and magnetic resonance imaging (MRI) scans were used to image the pituitary. The LCH treatment modality was based on organ involvement. The mean age at onset of DI was 27.6 years (range 15-60 years). One patient (11%) exhibited single organ involvement, while eight patients (89%) displayed multisystem organ involvement. On admittance, one patient had hypogonadotropic hypogonadism, one patient exhibited panhypopituitarism [hypogonadotropic hypogonadism, central hypothyroidism, hypocortisolism, and growth hormone (GH) deficiency], and four patients (44%) displayed hyperprolactinemia. The MRI data revealed infundibular enlargement in seven patients (78%), a thalamic mass in one patient (11%), and the absence of the bright spot in all patients. A single patient (11%) showed a mass in the pons that had a partially empty sella. The patients were treated with radiation therapy (RT), chemotherapy (CT), or a combination of both (RT+CT) and were followed up for a median of 91.8 months (range 2-318 months). Seven patients were assessed during the follow-up period, of whom four patients (57.1%) developed anterior pituitary hormone deficiency, three (43%) were diagnosed with GH deficiency, and one (14%) exhibited gonadotropin deficiency. The gonadotropin deficiency in the patient, which was diagnosed on admittance, was resolved during the follow-up period. DI persisted in all patients, and the conditions of the seven patients who have remained on follow-up are stable. In the present study, patients with LCH exhibited altered function in the anterior pituitary as well as the posterior pituitary, which may be due to the natural course of the disease or the effects of treatment. The present findings indicate that anterior pituitary function should be assessed in LCH patients on admittance and during follow-up, especially in LCH patients with multisystem organ involvement.

Entities:  

Mesh:

Year:  2014        PMID: 25209890     DOI: 10.1007/s12020-014-0408-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  48 in total

1.  Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH).

Authors:  P Makras; C Samara; M Antoniou; A Zetos; D Papadogias; Z Nikolakopoulou; E Andreakos; G Toloumis; G Kontogeorgos; G Piaditis; G A Kaltsas
Journal:  Neuroradiology       Date:  2005-11-15       Impact factor: 2.804

Review 2.  Pathogenesis of Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Mark Fleming; Barrett J Rollins
Journal:  Annu Rev Pathol       Date:  2012-08-06       Impact factor: 23.472

3.  Thyroid involvement by malignant histiocytosis of Langerhans' cell type.

Authors:  S Kitahama; M Iitaka; T Shimizu; N Serizawa; N Fukasawa; S Miura; S Kawasaki; K Yamanaka; Y Kawakami; S Murakami; J Ishii; S Katayama
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

4.  A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.

Authors: 
Journal:  Arch Dis Child       Date:  1996-07       Impact factor: 3.791

5.  Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study.

Authors:  Jean Donadieu; Maria-Alejandra Rolon; Caroline Thomas; Laurence Brugieres; Dominique Plantaz; Jean François Emile; Didier Frappaz; Michel David; Raja Brauner; Thierry Genereau; Dominique Debray; Sylvie Cabrol; Marie-Anne Barthez; Khé Hoang-Xuan; Michel Polak
Journal:  J Pediatr       Date:  2004-03       Impact factor: 4.406

6.  Anterior pituitary function and computed tomography/magnetic resonance imaging in patients with Langerhans cell histiocytosis and diabetes insipidus.

Authors:  V Broadbent; D B Dunger; E Yeomans; B Kendall
Journal:  Med Pediatr Oncol       Date:  1993

7.  Autoimmune cranial diabetes insipidus: its association with other endocrine diseases and with histiocytosis X.

Authors:  W A Scherbaum; J A Wass; G M Besser; G F Bottazzo; D Doniach
Journal:  Clin Endocrinol (Oxf)       Date:  1986-10       Impact factor: 3.478

8.  Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Authors:  Riccardo Haupt; Vasanta Nanduri; Maria Grazia Calevo; Cecilia Bernstrand; Jorge L Braier; Valerie Broadbent; Guadalupe Rey; Kenneth L McClain; Gritta Janka-Schaub; R Maarten Egeler
Journal:  Pediatr Blood Cancer       Date:  2004-05       Impact factor: 3.167

Review 9.  Endocrine manifestations in Langerhans cell histiocytosis.

Authors:  Polyzois Makras; Krystallenia I Alexandraki; George P Chrousos; Ashley B Grossman; Gregory A Kaltsas
Journal:  Trends Endocrinol Metab       Date:  2007-06-27       Impact factor: 12.015

10.  The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis.

Authors:  D B Dunger; V Broadbent; E Yeoman; J R Seckl; S L Lightman; D B Grant; J Pritchard
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

View more
  7 in total

1.  Langerhans cell histiocytosis and pituitary function.

Authors:  Polyzois Makras; Gregory Kaltsas
Journal:  Endocrine       Date:  2015-01-01       Impact factor: 3.633

2.  Hyperosmolar coma in a patient with hypothalamic Langerhans cell histiocytosis.

Authors:  Ivan Kruljac; Goran Rinčić; Hrvoje Ivan Pećina
Journal:  Endocrine       Date:  2015-07-07       Impact factor: 3.633

3.  Infantile-Onset Isolated Neurohypophyseal Langerhans Cell Histiocytosis with Central Diabetes Insipidus: A Case Report.

Authors:  Mizuki Tani; Shota Hiroshima; Hidetoshi Sato; Kentaro Sawano; Yohei Ogawa; Masaru Imamura; Makoto Oishi; Keisuke Nagasaki
Journal:  Children (Basel)       Date:  2022-05-13

4.  Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis.

Authors:  Zhen Huo; Tao Lu; Zhiyong Liang; Fan Ping; Jie Shen; Jingjing Lu; Wenbing Ma; Dachun Zhao; Dingrong Zhong
Journal:  Diagn Pathol       Date:  2016-10-19       Impact factor: 2.644

5.  Isolated Langerhans cell histiocytosis in the hypothalamic-pituitary region: a case report.

Authors:  Weibin Zhou; Jia Rao; Chengjiang Li
Journal:  BMC Endocr Disord       Date:  2019-12-19       Impact factor: 2.763

6.  Educational Case: Langerhans cell histiocytosis.

Authors:  Jonathan Light; Michele Retrouvey; Richard M Conran
Journal:  Acad Pathol       Date:  2022-05-12

7.  Multisystem involvement Langerhans cell histiocytosis in an adult: A case report.

Authors:  Bei-Bei Wang; Jun-Ru Ye; Yun-Lei Li; Yi Jin; Zhong-Wei Chen; Jian-Min Li; Yu-Ping Li
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.